El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

716082.pdf (842.98 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-03-10

Llicència de publicació

cc-by-nc-nd (c) Sociedad Española de Nefrología, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183577

Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.nefro.2021.01.002

Resum

Fabry disease may be treated by enzyme replacement therapy (ERT), but the impact of chronic kidney disease (CKD) on the response to therapy remains unclear. The aim of the present study was to analyse the incidence and predictors of clinical events in patients on ERT. Study design: Multicentre retrospective observational analysis of patients diagnosed and treated with ERT for Fabry disease. The primary outcome was the first renal, neurological or cardiological events or death during a follow-up of 60 months (24-120). Results: In 69 patients (42 males, 27 females, mean age 44.6±13.7 years), at the end of follow-up, eGFR and the left ventricular septum thickness remained stable and the urinary albumin: creatinine ratio tended to decrease, but this decrease only approached significance in patients on agalsidase-beta (242-128mg/g (p=0.05). At the end of follow-up, 21 (30%) patients had suffered an incident clinical event: 6 renal, 2 neurological and 13 cardiological (including 3 deaths). Events were more frequent in patients with baseline eGFR≤60ml/min/1.73m2 (log Rank 12.423, p=0.001), and this remained significant even after excluding incident renal events (log Rank 4.086, p=0.043) and in males and in females. Lower baseline eGFR was associated with a 3- to 7-fold increase the risk of clinical events in different Cox models. Conclusions: GFR at the initiation of ERT is the main predictor of clinical events, both in males and in females, suggesting that start of ERT prior to the development of CKD is associated with better outcomes.

Matèries

Malalties del ronyó, Malaltia de Fabry, Assaigs clínics, Enzims

Matèries (anglès)

Kidney diseases, Fabry's disease, Clinical trials, Enzymes

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GOICOECHEA, Marian, GOMEZ PRECIADO, Francisco, BENITO, Silvia, TORRAS AMBRÒS, Joan, TORRA, Roser, HUERTA, Ana, RESTREPO, Alejandra, UGALDE, Jessica, ASTUDILLO, Daniela estefania, AGRAZ, Irene, LOPEZ MENDOZA, Manuel, ARRIBA, Gabriel de, CORCHETE, Elena, QUIROGA, Borja, GUTIERREZ, Maria jose, MARTIN CONDE, Maria luisa, LOPES, Vanessa, RAMOS, Carmela, MENDEZ, Irene, CAO, Mercedes, DOMINGUEZ, Fernando, ORTIZ, Alberto, Spanish Group for the Study of Glomerular Diseases (GLOSEN). Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. _Nefrología_. 2021. Vol. 41, núm. 6, pàgs. 652-660. [consulta: 8 de gener de 2026]. ISSN: 0211-6995. [Disponible a: https://hdl.handle.net/2445/183577]

Exportar metadades

JSON - METS

Compartir registre